{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:40:13Z","timestamp":1780072813602,"version":"3.54.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2006,8,17]],"date-time":"2006-08-17T00:00:00Z","timestamp":1155772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1038\/nrc1974","type":"journal-article","created":{"date-parts":[[2006,8,17]],"date-time":"2006-08-17T10:31:37Z","timestamp":1155810697000},"page":"729-734","source":"Crossref","is-referenced-by-count":1101,"title":["mTOR and cancer: insights into a complex relationship"],"prefix":"10.1038","volume":"6","author":[{"given":"David M.","family":"Sabatini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,8,17]]},"reference":[{"key":"BFnrc1974_CR1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","volume":"17","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov, D. D., Ali, S. M. & Sabatini, D. M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596\u2013603 (2005).","journal-title":"Curr. Opin. Cell Biol."},{"key":"BFnrc1974_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0092-8674(01)00332-4","volume":"105","author":"N Tapon","year":"2001","unstructured":"Tapon, N., Ito, N., Dickson, B. J., Treisman, J. E. & Hariharan, I. K. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105, 345\u2013355 (2001).","journal-title":"Cell"},{"key":"BFnrc1974_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ncb847","volume":"4","author":"X Gao","year":"2002","unstructured":"Gao, X. et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nature Cell Biol. 4, 699\u2013704. (2002).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1974_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/ncb996","volume":"5","author":"LJ Saucedo","year":"2003","unstructured":"Saucedo, L. J. et al. Rheb promotes cell growth as a component of the insulin\/TOR signalling network. Nature Cell Biol. 5, 566\u2013571 (2003).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1974_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/ncb995","volume":"5","author":"H Stocker","year":"2003","unstructured":"Stocker, H. et al. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nature Cell Biol. 5, 559\u2013565 (2003).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1974_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/ncb999","volume":"5","author":"Y Zhang","year":"2003","unstructured":"Zhang, Y. et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nature Cell Biol. 5, 578\u2013581 (2003).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1974_CR7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C. & Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259\u20131268 (2003).","journal-title":"Curr. Biol."},{"key":"BFnrc1974_CR8","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","volume":"11","author":"A Garami","year":"2003","unstructured":"Garami, A. et al. Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11, 1457\u20131466 (2003).","journal-title":"Mol. Cell"},{"key":"BFnrc1974_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cub.2005.02.053","volume":"15","author":"X Long","year":"2005","unstructured":"Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K. & Avruch, J. Rheb binds and regulates the mTOR kinase. Curr. Biol 15, 702\u2013713 (2005).","journal-title":"Curr. Biol"},{"key":"BFnrc1974_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/ncb839","volume":"4","author":"K Inoki","year":"2002","unstructured":"Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biol. 4, 648\u2013657 (2002).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1974_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/ncb840","volume":"4","author":"CJ Potter","year":"2002","unstructured":"Potter, C. J., Pedraza, L. G. & Xu, T. Akt regulates growth by directly phosphorylating Tsc2. Nature Cell Biol. 4, 658\u2013665. (2002).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1974_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","volume":"10","author":"BD Manning","year":"2002","unstructured":"Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J. & Cantley, L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol. Cell 10, 151\u2013162 (2002).","journal-title":"Mol. Cell"},{"key":"BFnrc1974_CR13","doi-asserted-by":"publisher","first-page":"37288","DOI":"10.1074\/jbc.M303257200","volume":"278","author":"AR Tee","year":"2003","unstructured":"Tee, A. R., Anjum, R. & Blenis, J. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase\/Akt-dependent and -independent phosphorylation of tuberin. J. Biol. Chem. 278, 37288\u201337296 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1974_CR14","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1073\/pnas.0503224102","volume":"102","author":"CM Johannessen","year":"2005","unstructured":"Johannessen, C. M. et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl Acad. Sci. USA 102, 8573\u20138578 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1974_CR15","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.1073\/pnas.0502857102","volume":"102","author":"Z Feng","year":"2005","unstructured":"Feng, Z., Zhang, H., Levine, A. J. & Jin, S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl Acad. Sci. USA 102, 8204\u20138209 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1974_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","volume":"6","author":"RJ Shaw","year":"2004","unstructured":"Shaw, R. J. et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91\u201399 (2004).","journal-title":"Cancer Cell"},{"key":"BFnrc1974_CR17","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1101\/gad.1199104","volume":"18","author":"MN Corradetti","year":"2004","unstructured":"Corradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A. & Guan, K. L. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz\u2013Jeghers syndrome. Genes Dev. 18, 1533\u20131538 (2004).","journal-title":"Genes Dev."},{"key":"BFnrc1974_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","volume":"115","author":"K Inoki","year":"2003","unstructured":"Inoki, K., Zhu, T. & Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577\u2013590 (2003).","journal-title":"Cell"},{"key":"BFnrc1974_CR19","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 18, 1926\u20131945 (2004).","journal-title":"Genes Dev."},{"key":"BFnrc1974_CR20","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1128\/MCB.21.15.5050-5062.2001","volume":"21","author":"A Takano","year":"2001","unstructured":"Takano, A. et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol. Cell. Biol. 21, 5050\u20135062 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc1974_CR21","doi-asserted-by":"crossref","first-page":"38052","DOI":"10.1074\/jbc.M106703200","volume":"276","author":"F Tremblay","year":"2001","unstructured":"Tremblay, F. & Marette, A. Amino acid and insulin signaling via the mTOR\/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J. Biol. Chem. 276, 38052\u201338060 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1974_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1210\/mend.14.6.0446","volume":"14","author":"T Haruta","year":"2000","unstructured":"Haruta, T. et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol. Endocrinol. 14, 783\u2013794 (2000).","journal-title":"Mol. Endocrinol."},{"key":"BFnrc1974_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1083\/jcb.200403069","volume":"166","author":"LS Harrington","year":"2004","unstructured":"Harrington, L. S. et al. The TSC1\u20132 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213\u2013223 (2004).","journal-title":"J. Cell Biol."},{"key":"BFnrc1974_CR24","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","volume":"14","author":"OJ Shah","year":"2004","unstructured":"Shah, O. J., Wang, Z. & Hunter, T. Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14, 1650\u20131656 (2004).","journal-title":"Curr. Biol."},{"key":"BFnrc1974_CR25","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1101\/gad.1314405","volume":"19","author":"L Ma","year":"2005","unstructured":"Ma, L. et al. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 19, 1779\u20131786 (2005).","journal-title":"Genes Dev."},{"key":"BFnrc1974_CR26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1101\/gad.1314605","volume":"19","author":"BD Manning","year":"2005","unstructured":"Manning, B. D. et al. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 19, 1773\u20131778 (2005).","journal-title":"Genes Dev."},{"key":"BFnrc1974_CR27","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt\/PKB by the rictor\u2013mTOR complex. Science 307, 1098\u20131101 (2005).","journal-title":"Science"},{"key":"BFnrc1974_CR28","doi-asserted-by":"publisher","first-page":"40406","DOI":"10.1074\/jbc.M508361200","volume":"280","author":"RC Hresko","year":"2005","unstructured":"Hresko, R. C. & Mueckler, M. mTOR\/RICTOR is the Ser473 kinase for Akt\/PKB in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406\u201340416 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1974_CR29","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"DD Sarbassov","year":"2004","unstructured":"Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296\u20131302 (2004).","journal-title":"Curr. Biol."},{"key":"BFnrc1974_CR30","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/ncb1183","volume":"6","author":"E Jacinto","year":"2004","unstructured":"Jacinto, E. et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biol. 6, 1122\u20131128 (2004).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1974_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"D-H Kim","year":"2002","unstructured":"Kim, D.-H. et al. mTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163\u2013175 (2002).","journal-title":"Cell"},{"key":"BFnrc1974_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","volume":"110","author":"K Hara","year":"2002","unstructured":"Hara, K. et al. Raptor, a binding partner of Target of Rapamycin (TOR), mediates TOR action. Cell 110, 177\u2013189 (2002).","journal-title":"Cell"},{"key":"BFnrc1974_CR33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0960-9822(03)00329-4","volume":"13","author":"SS Schalm","year":"2003","unstructured":"Schalm, S. S., Fingar, D. C., Sabatini, D. M. & Blenis, J. TOS Motif-mediated Raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13, 797\u2013806 (2003).","journal-title":"Curr. Biol."},{"key":"BFnrc1974_CR34","doi-asserted-by":"publisher","first-page":"15461","DOI":"10.1074\/jbc.C200665200","volume":"278","author":"H Nojima","year":"2003","unstructured":"Nojima, H. et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278, 15461\u201315464 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1974_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.molmed.2005.06.007","volume":"11","author":"DA Guertin","year":"2005","unstructured":"Guertin, D. A. & Sabatini, D. M. An expanding role for mTOR in cancer. Trends Mol. Med. 11, 353\u2013361 (2005).","journal-title":"Trends Mol. Med."},{"key":"BFnrc1974_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol. Cell 22, 159\u2013168 (2006).","journal-title":"Mol. Cell"},{"key":"BFnrc1974_CR37","doi-asserted-by":"crossref","unstructured":"Frias, M. A. et al. mSin1 is necessary for Akt\/PKB phosphorylation and its isoforms define three distinct mTORC2s. Curr. Biol. (in the press).","DOI":"10.1016\/j.cub.2006.08.001"},{"key":"BFnrc1974_CR38","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1158\/0008-5472.CAN-05-4510","volume":"66","author":"X Jiang","year":"2006","unstructured":"Jiang, X. & Yeung, R. S. Regulation of microtubule-dependent protein transport by the TSC2\/mammalian target of rapamycin pathway. Cancer Res. 66, 5258\u20135269 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc1974_CR39","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","volume":"107","author":"DT Teachey","year":"2006","unstructured":"Teachey, D. T. et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107, 1149\u20131155 (2006).","journal-title":"Blood"},{"key":"BFnrc1974_CR40","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1182\/blood-2005-03-0929","volume":"106","author":"R Avellino","year":"2005","unstructured":"Avellino, R. et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 106, 1400\u20131406 (2005).","journal-title":"Blood"},{"key":"BFnrc1974_CR41","first-page":"364","volume":"63","author":"KN Thimmaiah","year":"2003","unstructured":"Thimmaiah, K. N. et al. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3-kinase\u2013Akt signaling pathways. Cancer Res. 63, 364\u2013374 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1974_CR42","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ygyno.2005.12.019","volume":"102","author":"O Treeck","year":"2006","unstructured":"Treeck, O., Wackwitz, B., Haus, U. & Ortmann, O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol. 102 292\u2013299 (2006).","journal-title":"Gynecol. Oncol."},{"key":"BFnrc1974_CR43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","volume":"120","author":"I Beuvink","year":"2005","unstructured":"Beuvink, I. et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747\u2013759 (2005).","journal-title":"Cell"},{"key":"BFnrc1974_CR44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1158\/1535-7163.MCT-04-0137","volume":"4","author":"M Hahn","year":"2005","unstructured":"Hahn, M. et al. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1\/MEK\/ERK, Akt, and JNK signal transduction pathways. Mol. Cancer Ther. 4, 457\u2013470 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrc1974_CR45","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/sj.cdd.4401660","volume":"12","author":"C Fumarola","year":"2005","unstructured":"Fumarola, C., La Monica, S., Alfieri, R. R., Borra, E. & Guidotti, G. G. Cell size reduction induced by inhibition of the mTOR\/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ. 12, 1344\u20131357 (2005).","journal-title":"Cell Death Differ."},{"key":"BFnrc1974_CR46","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","volume":"23","author":"E Galanis","year":"2005","unstructured":"Galanis, E. et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294\u20135304 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1974_CR47","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","volume":"23","author":"SM Chang","year":"2005","unstructured":"Chang, S. M. et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23, 357\u2013361 (2005).","journal-title":"Invest. New Drugs"},{"key":"BFnrc1974_CR48","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins, M. B. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909\u2013918 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1974_CR49","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig, T. E. et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23, 5347\u20135356 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1974_CR50","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"DN Franz","year":"2006","unstructured":"Franz, D. N. et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59, 490\u2013498 (2006).","journal-title":"Ann. Neurol."},{"key":"BFnrc1974_CR51","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.bbrc.2003.10.170","volume":"312","author":"M Hengstschlager","year":"2003","unstructured":"Hengstschlager, M., Rosner, M., Fountoulakis, M. & Lubec, G. Tuberous sclerosis genes regulate cellular 14\u20133\u20133 protein levels. Biochem. Biophys. Res. Commun. 312, 676\u2013683 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrc1974_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/35010550","volume":"2","author":"RF Lamb","year":"2000","unstructured":"Lamb, R. F. et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nature Cell Biol. 2, 281\u2013287 (2000).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1974_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11033-005-0984-x","volume":"32","author":"J Yuan","year":"2005","unstructured":"Yuan, J. et al. Identification and characterization of RHEBL1, a novel member of Ras family, which activates transcriptional activities of NF-kB. Mol. Biol. Rep. 32, 205\u2013214 (2005).","journal-title":"Mol. Biol. Rep."},{"key":"BFnrc1974_CR54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/jb\/mvi046","volume":"137","author":"K Saito","year":"2005","unstructured":"Saito, K., Araki, Y., Kontani, K., Nishina, H. & Katada, T. Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin. J. Biochem. 137, 423\u2013430 (2005).","journal-title":"J. Biochem."},{"key":"BFnrc1974_CR55","doi-asserted-by":"publisher","first-page":"29930","DOI":"10.1074\/jbc.M402591200","volume":"279","author":"M Karbowniczek","year":"2004","unstructured":"Karbowniczek, M. et al. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J. Biol. Chem. 279, 29930\u201329937 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1974_CR56","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1128\/MCB.17.2.921","volume":"17","author":"WM Yee","year":"1997","unstructured":"Yee, W. M. & Worley, P. F. Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals. Mol. Cell. Biol. 17, 921\u2013933 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc1974_CR57","doi-asserted-by":"crossref","unstructured":"Karbowniczek, M., Robertson, G. P. & Henske, E. P. Rheb inhibits C-Raf activity and B-Raf\/C-Raf heterodimerization. J. Biol. Chem. 27 Jun 2006 (doi:10.1074\/jbc.M605273200).","DOI":"10.1074\/jbc.M605273200"},{"key":"BFnrc1974_CR58","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/nn1566","volume":"8","author":"SF Tavazoie","year":"2005","unstructured":"Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J. & Sabatini, B. L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nature Neurosci. 8, 1727\u20131734 (2005).","journal-title":"Nature Neurosci."},{"key":"BFnrc1974_CR59","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/0008-5472.CAN-05-3375","volume":"66","author":"F Kaper","year":"2006","unstructured":"Kaper, F., Dornhoefer, N. & Giaccia, A. J. Mutations in the PI3K\/PTEN\/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 66, 1561\u20131569 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc1974_CR60","doi-asserted-by":"publisher","first-page":"10314","DOI":"10.1073\/pnas.171076798","volume":"98","author":"MS Neshat","year":"2001","unstructured":"Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc. Natl Acad. Sci. USA 98, 10314\u201310319 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1974_CR61","doi-asserted-by":"publisher","first-page":"10320","DOI":"10.1073\/pnas.171060098","volume":"98","author":"K Podsypanina","year":"2001","unstructured":"Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice. Proc. Natl Acad. Sci. USA 98, 10320\u201310325 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1974_CR62","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm1052","volume":"10","author":"PK Majumder","year":"2004","unstructured":"Majumder, P. K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Med. 10, 594\u2013601 (2004).","journal-title":"Nature Med."},{"key":"BFnrc1974_CR63","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332\u2013337 (2004).","journal-title":"Nature"},{"key":"BFnrc1974_CR64","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","volume":"23","author":"S Chan","year":"2005","unstructured":"Chan, S. et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23, 5314\u20135322 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1974_CR65","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun, S. Y. et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052\u20137058 (2005).","journal-title":"Cancer Res."},{"key":"BFnrc1974_CR66","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500\u20131508 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc1974_CR67","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ccr.2006.03.029","volume":"9","author":"QW Fan","year":"2006","unstructured":"Fan, Q. W. et al. A dual PI3 kinase\/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341\u2013349 (2006).","journal-title":"Cancer Cell"},{"key":"BFnrc1974_CR68","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","volume":"125","author":"ZA Knight","year":"2006","unstructured":"Knight, Z. A. et al. A pharmacological map of the PI3-K-family defines a role for p110\u03b1 in insulin signaling. Cell 125, 733\u2013747 (2006).","journal-title":"Cell"},{"key":"BFnrc1974_CR69","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature04694","volume":"441","author":"LC Foukas","year":"2006","unstructured":"Foukas, L. C. et al. Critical role for the p110\u03b1 phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366\u2013370 (2006).","journal-title":"Nature"},{"key":"BFnrc1974_CR70","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Med. 8, 128\u2013135 (2002).","journal-title":"Nature Med."},{"key":"BFnrc1974_CR71","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/01.TP.0000115344.18025.0B","volume":"77","author":"JM Campistol","year":"2004","unstructured":"Campistol, J. M., Gutierrez-Dalmau, A. & Torregrosa, J. V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77, 760\u2013762 (2004).","journal-title":"Transplantation"},{"key":"BFnrc1974_CR72","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa042831","volume":"352","author":"G Stallone","year":"2005","unstructured":"Stallone, G. et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352, 1317\u20131323 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc1974_CR73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/1568005033481222","volume":"3","author":"Y Aoki","year":"2003","unstructured":"Aoki, Y. & Tosato, G. Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr. Drug Targets Infect. Disord. 3, 115\u2013128 (2003).","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"BFnrc1974_CR74","doi-asserted-by":"crossref","unstructured":"Phung, T. L. et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell (in the press).","DOI":"10.1016\/j.ccr.2006.07.003"},{"key":"BFnrc1974_CR75","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson, C. C. et al. Regulation of hypoxia-inducible factor 1\u03b1 expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004\u20137014 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc1974_CR76","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","volume":"66","author":"D Del Bufalo","year":"2006","unstructured":"Del Bufalo, D. et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66, 5549\u20135554 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc1974_CR77","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nm1337","volume":"12","author":"GV Thomas","year":"2006","unstructured":"Thomas, G. V. et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Med. 12, 122\u2013127 (2006).","journal-title":"Nature Med."},{"key":"BFnrc1974_CR78","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-03-0502","volume":"10","author":"CJ Bruns","year":"2004","unstructured":"Bruns, C. J. et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin. Cancer Res. 10, 2109\u20132119 (2004).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1974_CR79","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1161\/01.RES.0000022200.71892.9F","volume":"90","author":"I Shiojima","year":"2002","unstructured":"Shiojima, I. & Walsh, K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 90, 1243\u20131250 (2002).","journal-title":"Circ. Res."},{"key":"BFnrc1974_CR80","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1535-6108(02)00237-4","volume":"3","author":"S Montaner","year":"2003","unstructured":"Montaner, S. et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3, 23\u201336 (2003).","journal-title":"Cancer Cell"},{"key":"BFnrc1974_CR81","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/01.cco.0000174039.69656.2b","volume":"17","author":"ME Williams","year":"2005","unstructured":"Williams, M. E. & Densmore, J. J. Biology and therapy of mantle cell lymphoma. Curr. Opin. Oncol. 17, 425\u2013431 (2005).","journal-title":"Curr. Opin. Oncol."},{"key":"BFnrc1974_CR82","doi-asserted-by":"publisher","first-page":"29864","DOI":"10.1074\/jbc.273.45.29864","volume":"273","author":"RC Muise-Helmericks","year":"1998","unstructured":"Muise-Helmericks, R. C. et al. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase\/Akt-dependent pathway. J. Biol. Chem. 273, 29864\u201329872 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1974_CR83","doi-asserted-by":"publisher","first-page":"C281","DOI":"10.1152\/ajpcell.00422.2003","volume":"287","author":"N Gao","year":"2004","unstructured":"Gao, N. et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K\/AKT\/mTOR\/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell. Physiol. 287, C281\u2013C291 (2004).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"BFnrc1974_CR84","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-05-1672","volume":"66","author":"M Law","year":"2006","unstructured":"Law, M. et al. Rapamycin disrupts cyclin\/cyclin-dependent kinase\/p21\/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res. 66, 1070\u20131080 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc1974_CR85","doi-asserted-by":"crossref","first-page":"22825","DOI":"10.1016\/S0021-9258(18)41602-X","volume":"268","author":"MW Albers","year":"1993","unstructured":"Albers, M. W. et al. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1\u2013Cdk association in early G1 of an osteosarcoma cell line. J. Biol. Chem. 268, 22825\u201322829 (1993).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1974_CR86","doi-asserted-by":"publisher","first-page":"14424","DOI":"10.1074\/jbc.273.23.14424","volume":"273","author":"S Hashemolhosseini","year":"1998","unstructured":"Hashemolhosseini, S. et al. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem. 273, 14424\u201314429 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1974_CR87","first-page":"1433","volume":"90","author":"S Hipp","year":"2005","unstructured":"Hipp, S. et al. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90, 1433\u20131434 (2005).","journal-title":"Haematologica"},{"key":"BFnrc1974_CR88","doi-asserted-by":"crossref","unstructured":"Rudelius, M. et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 27 Apr 2006 (doi:10.1182\/blood-2006-04-015586).","DOI":"10.1182\/blood-2006-04-015586"},{"key":"BFnrc1974_CR89","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1128\/MCB.24.21.9508-9516.2004","volume":"24","author":"YG Gangloff","year":"2004","unstructured":"Gangloff, Y. G. et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 24, 9508\u20139516 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc1974_CR90","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1128\/MCB.24.15.6710-6718.2004","volume":"24","author":"M Murakami","year":"2004","unstructured":"Murakami, M. et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24, 6710\u20136718 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc1974_CR91","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.7164\/antibiotics.37.1231","volume":"37","author":"CP Eng","year":"1984","unstructured":"Eng, C. P., Sehgal, S. N. & Vezina, C. Activity of rapamycin (AY-22, 989) against transplanted tumors. J. Antibiot. 37, 1231\u20131237 (1984).","journal-title":"J. Antibiot."},{"key":"BFnrc1974_CR92","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1097-2765(03)00114-X","volume":"11","author":"DH Kim","year":"2003","unstructured":"Kim, D. H. et al. G\u03b2L, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11, 895\u2013904 (2003).","journal-title":"Mol. Cell"},{"key":"BFnrc1974_CR93","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","volume":"10","author":"R Loewith","year":"2002","unstructured":"Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457\u2013468 (2002).","journal-title":"Mol. Cell"}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc1974.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1974","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1974.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:20:42Z","timestamp":1684466442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc1974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,17]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["BFnrc1974"],"URL":"https:\/\/doi.org\/10.1038\/nrc1974","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,17]]}}}